Funding for this research was provided by:
Kyorin Pharmaceutical Co., Ltd.
Japan Agency for Medical Research and Development (JP17bm0804007, JP19bm0704037)
Article History
Received: 3 October 2021
Accepted: 2 November 2021
First Online: 1 January 2022
Declarations
:
: A.M. is an employee, received research funding, and are shareholders of Kyorin Pharmaceutical Co., Ltd. S.G. is one of the founders and shareholders of HiLung Inc. and is one of the inventors of Kyoto University’s patents related to the methods of generating human PSC-derived lung lineage cells. This research was funded by Kyorin Pharmaceutical Co. Ltd. and by AMED (JP17bm0804007 to T.H. and JP19bm0704037 to S.G.).